Search Results
Jun 25, 2026, 12:02 ET David Villa Appointed as Global Brand Ambassador for BitradeX
ecosystem platform, BitradeX continues to build around user value and long-term ecosystem growth. Its core business areas include AiBot, BXC Ecosystem, BTX Card, and other initiatives designed to support the development of a broader global digital asset ecosystem.With Villa joining as
More news about: BitradeX
May 18, 2026, 07:54 ET Biotheryx Announces Data from its Phase 1 Dose Escalation Study of BTX-9341, a First-in-Class, Potent and Selective CDK4/6 Degrader, for the Treatment of Advanced/Metastatic HR+/HER2- Breast Cancer
Survival (PFS).About BTX-9341BTX-9341 is a first-in-class, oral degrader of CDK4/6, important targets for a range of cancers and clinically validated in HR+/HER2- breast cancer. In preclinical breast cancer models, BTX-9341 demonstrated enhanced activity compared
More news about: Biotheryx, Inc.
May 09, 2026, 02:53 ET BitradeX BXC First Two Subscription Rounds Sell Out, Total Subscriptions Exceed 14M USDT
token. Its value framework is linked to BitradeX Capital's broader ecosystem, including its exchange business, AiBot quantitative strategies, BTX Card payments, and Labs incubation platform. Public information indicates that BXC holders may receive staking rewards, benefit from ecosystem buybacks
More news about: BitradeX Capital
May 04, 2026, 07:55 ET Biotheryx to Present Results from its Phase 1A Dose Escalation Study of BTX-9341 for the Treatment of HR+/HER2- Breast Cancer at the 2026 European Society for Medical Oncology Breast Cancer Annual Congress
Friday, May 8, 2026 | 8:30-10:00 AMAbout BTX-9341BTX-9341 is a first-in-class, oral degrader of CDK4/6, important targets for a range of cancers and clinically validated in HR+/HER2- breast cancer. In preclinical breast cancer models, BTX-9341 demonstrated superiority to CDK4/6 inhibitors
More news about: Biotheryx, Inc.
Apr 13, 2026, 03:05 ET BitradeX Announces Strategic Ecosystem Upgrade and Launch of BitradeX Capital with BXC Token
attracted a growing base of active users and managed assets, becoming a key driver of both user growth and yield generation.On the payment layer, the BTX Card connects digital assets with real-world consumption. By supporting multi-region transactions and global merchant networks, it enables seamless crypto
More news about: Bitradex
Mar 18, 2026, 07:58 ET Biotheryx Announces First Patient Dosed in the Dose Expansion Phase of BTX-9341-101 for the Treatment of HR+/HER2- Breast Cancer
inhibitors, and we look forward to further assessing BTX-9341 in combination with fulvestrant to improve outcomes for patients with HR+/HER2- breast cancer who have previously received CDK4/6 inhibitor therapy." About BTX-9341BTX-9341 is a first-in-class, oral degrader of CDK4/6,
More news about: Biotheryx, Inc.
Jan 19, 2026, 20:00 ET LOTTE Chemical Indonesia, Milliken, dan Tederic Gelar Seminar tentang Solusi Polipropilena Mutakhir
memiliki kapasitas produksi tahunan sebesar 1 juta ton etilena, 520.000 ton propilena, 350.000 ton polipropilena, 140.000 ton butadiena, serta 400.000 ton BTX (benzena, toluena, dan xilena)."Inovasi tumbuh melalui kolaborasi," kata Daniel Tanzil, Country Manager, Plastic Additives Business,
More news about: Milliken
Nov 17, 2025, 08:05 ET Biotheryx Announces Completion of Enrollment in Phase 1a Clinical Trial of BTX-9341 for the Treatment HR+/HER2- Breast Cancer
About BTX-9341 BTX-9341 is a first-in-class, oral degrader of CDK4/6, important targets for a range of cancers and clinically validated in HR+/HER2- breast cancer. In preclinical breast cancer models, BTX-9341 demonstrated superiority
More news about: Biotheryx, Inc.
Oct 20, 2025, 17:31 ET Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsight
attracting investment and clinical development. Furthermore, the launch of emerging therapies such as INT230-6, Alrizomadlin (APG-115), BOXR1030, BTX-A51, CEB-01, Letetresgene Autoleucel, and others will propel the market.
More news about: DelveInsight Business Research, LLP